DGAP-News: Vita 34 AG: Expansion of Product Range with Permit for Collecting Umbilical Cord Tissue
(firmenpresse) - DGAP-News: Vita 34 AG / Key word(s): Miscellaneous
Vita 34 AG: Expansion of Product Range with Permit for Collecting
Umbilical Cord Tissue
26.09.2013 / 08:01
---------------------------------------------------------------------
Vita 34 AG: Expansion of Product Range with Permit for Collecting Umbilical
Cord Tissue
- Unique characteristic: Vita 34 is the only company in Germany that can
store umbilical cord tissue along with umbilical cord blood
- The storage of umbilical cord tissue offers additional sales and
revenue potential for Vita 34
Leipzig, 26 September 2013 - Vita 34 AG (WKN A0BL84), Europe's oldest
private stem cell bank and a specialist for cryo-preservation, has been
granted a permit for collecting umbilical cord tissue in Saxony. Back in
May 2013 Vita 34 had already received permission for the processing,
cryo-preservation and storage of umbilical cord blood, after a successful
inspection on the part of the State Direction Saxony and the Paul Ehrlich
Institute. In accordance with the permit for collecting umbilical cord
blood just granted in line with§20b German Pharmaceuticals Act, Vita 34 is
the only private stem cell bank in Germany that can store not only
umbilical cord blood, but also umbilical cord tissue according to Good
Manufacturing Practice (GMP) guidelines, thus expanding the company's
product range.
The mesenchymal stem cells (MSC), which are found particularly in the
connective tissue of the umbilical cord blood, are responsible for the
development of bones, cartilage, muscles and tendons in the human body.
Thus, they offer an important medical base material for creating the
corresponding tissue in the laboratory following a disease or an accident.
In addition, MSCs have immune-modulatory characteristics, which can be used
when treating a disruptive immune reaction, for example, as is found in
graft-versus-host disease (GVHD).
Dr. AndréGerth, Chairman of the Management Board of Vita 34 AG: 'With the
permit for collecting umbilical cord tissue we have a really unique selling
point on the German market. Physicians and midwives in birthing clinics are
receiving this topic with great interest, and are expressing themselves
positively concerning this additional option for storing stem cells when
they speak with our training representatives. The additional storage of
umbilical cord tissue provides Vita 34 with new sales and revenue
potential. Here, in Europe already some 80% of expecting parents who have
the umbilical cord blood of their children collected and stored, opt
additionally for the preservation of the umbilical cord tissue.'
Vita 34 is now pursuing the goal of expanding the collection permit
throughout Germany in the short-term, and of entering into contracts for
umbilical cord tissue collection with all of its roughly 800 partner
clinics. 'We see a great potential for the therapeutic application of
mesenchymal stem cells, since research into MSCs is continuing to be done
with an intense focus in the field of regenerative medicine. It is
remarkable that some two-thirds of the nearly 200 clinical studies are
counting on autologous, that is the body's own mesenchymal stem cells,'
summarizes Dr. AndréGerth.
Company Profile
Vita 34 was founded in 1997 as the first private umbilical cord blood bank
in Europe and, as a complete provider, offers collection logistics,
preparation and storage of umbilical cord blood and umbilical cord tissue.
The basis for its successful work is an outstanding position in the
technological segment of cryo-preservation. Here, cells and tissues are
preserved alive at temperatures around minus 190 degrees Celsius, and can
be used if needed in the context of medical treatment. Parents of more than
95,000 children are already taking advantage of this offering and have
provided for their children with a stem cell deposit at this Leipzig
company.
End of Corporate News
---------------------------------------------------------------------
26.09.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: ir(at)vita34.de
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
231981 26.09.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.09.2013 - 08:01 Uhr
Sprache: Deutsch
News-ID 300372
Anzahl Zeichen: 6162
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 247 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Vita 34 AG: Expansion of Product Range with Permit for Collecting Umbilical Cord Tissue"
steht unter der journalistisch-redaktionellen Verantwortung von
Vita 34 AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
